Get the Stockscreener App
123.85
3.85%
4.59
After Hours:
125.33
1.48
+1.19%
Illumina Inc stock is traded at $123.85, with a volume of 2.37M.
It is up +3.85% in the last 24 hours and up +25.15% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$119.26
Open:
$119.26
24h Volume:
2.37M
Relative Volume:
1.38
Market Cap:
$18.92B
Revenue:
$4.28B
Net Income/Loss:
$1.26B
P/E Ratio:
15.69
EPS:
7.8957
Net Cash Flow:
$943.00M
1W Performance:
+2.64%
1M Performance:
+25.15%
6M Performance:
+56.04%
1Y Performance:
-9.59%
1-Day Range:
$118.97
$125.41
1-Week Range:
$117.50
$126.94
52-Week Range:
$68.70
$153.06
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
123.85 | 18.22B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
587.48 | 215.18B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
227.39 | 156.94B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
725.91 | 55.05B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
151.25 | 41.12B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
224.90 | 36.97B | 15.90B | 1.28B | 2.21B | 7.2842 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - TradingView
Will Illumina Inc. (ILU) stock keep high P E multiplesWeekly Market Report & Daily Chart Pattern Signal Reports - newser.com
Genomic Biomarker Market By Top Companies Illumina,Thermo - openPR.com
Is Illumina Inc. (ILU) stock positioned for digital growth eraSwing Trade & Daily Price Action Insights - newser.com
Is Illumina Inc. forming a bottoming baseRate Cut & Real-Time Volume Analysis - newser.com
Committed to accelerating precision medicine in China - Illumina
Does Illumina’s 20% Surge Signal a Reversal After GRAIL Divestiture News? - Yahoo Finance
Will Illumina Inc. (ILU) stock justify high valuationJuly 2025 Recap & Technical Buy Zone Confirmations - newser.com
Will Illumina Inc. (ILU) stock deliver stable dividends2025 Retail Activity & Safe Capital Growth Tips - newser.com
Will Illumina Inc. (ILU) stock test record highs in 2025Jobs Report & Risk Controlled Swing Alerts - newser.com
Real time pattern detection on Illumina Inc. stockRecession Risk & Daily Profit Maximizing Tips - newser.com
Why analysts maintain buy rating on Illumina Inc. (ILU) stockEarnings Beat & Risk Controlled Swing Trade Alerts - newser.com
What moving averages say about Illumina Inc.2025 Market Outlook & Smart Swing Trading Alerts - newser.com
Is Illumina Inc. (ILU) stock inflation resilient2025 Stock Rankings & AI Forecasted Stock Moves - newser.com
Transcript : Illumina, Inc. Presents at 7th Annual Wolfe Research Healthcare Conference, Nov-19-2025 09 - MarketScreener
Candlestick signals on Illumina Inc. stock todayIPO Watch & Consistent Growth Stock Picks - newser.com
Illumina at Wolfe Research Conference: Strategic Growth Amid Challenges - Investing.com India
Illumina at Wolfe Research Conference: Strategic Growth Amid Challenges By Investing.com - Investing.com Canada
3 Reasons to Sell ILMN and 1 Stock to Buy Instead - Finviz
Published on: 2025-11-19 04:40:33 - newser.com
Published on: 2025-11-18 23:37:24 - newser.com
Illumina sells GRAIL shares worth $79.85 million By Investing.com - Investing.com Australia
Illumina sells GRAIL shares worth $79.85 million - Investing.com
Tackling antimicrobial resistance, one genome at a time - Illumina
Illumina Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Leadership Perspectives: Illumina leads the industry in genomic AI - Illumina
The Bull Case For Illumina (ILMN) Could Change Following Export Ban Easing in China—Learn Why - simplywall.st
Why Illumina Inc. stock is considered a top pickInsider Selling & Intraday High Probability Alerts - newser.com
Why The Narrative Around Illumina Is Shifting After Recent Analyst Upgrades and Sector Changes - Yahoo Finance
Demystifying MRD with BloodPac: Navigating clinical and technical pathways for comprehensive cancer monitoring - Illumina
Why Illumina Inc. (ILU) stock benefits from AI revolution2025 Earnings Surprises & Proven Capital Preservation Methods - newser.com
Is Illumina Inc. stock a buy in volatile marketsIPO Watch & Free Fast Gain Swing Trade Alerts - newser.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):